PIMOBENDAN VETMEDICA 1,25 MG COMPRIME A CROQUER POUR CHIENS
国家: 法国
语言: 英文
来源: HMA (Heads of Medicines Agencies)
资料单张 有效成分:
pimobendan 1.25 mg
可用日期:
Boehringer Ingelheim Vetmedica GmbH
ATC代码:
QC01CE90
药物剂型:
Chewable tablet
治疗组:
pimobendane
治疗领域:
Dogs
授权日期:
2012-01-27
资料单张
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 1.25 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 1.25 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 1.25 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
1.25 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P01.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PREC
阅读完整的文件
产品特点
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 1.25 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 1.25 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 1.25 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
1.25 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P01.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PREC
阅读完整的文件
